Navigation Links
Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc
Date:9/8/2011

SAINT PAUL, Minn., Sept. 8, 2011 /PRNewswire/ -- Enterologics, Inc  (ELGO.OB) announced today that it has completed its acquisition of The BioBalance Corporation and its subsidiary BioBalance LLC from New York Health Care, Inc. ("NYHC").  With this purchase Enterologics acquired its first probiotic biotherapeutic product, E. coli M17, or Probactrix®.

E. coli M17 has an active Investigational New Drug application (IND) with the FDA for the indication chronic pouchitis.  Pouchitis is a complication that occurs in patients following surgical treatment of their ulcerative colitis.  This involves removing the colon and reconstructing a rectal pouch, a procedure called restorative proctocolectomy or ilealanal pouch anal anastomosis.  The pouch can become inflamed, accompanied by pain and frequent, sometimes bloody bowel movements, requiring antibiotic treatment.  While the population of pouchitis sufferers is small, the unmet treatment need is significant.  There are at present no FDA-approved drugs for treating this condition, although metronidazole and ciprofloxacin are typically prescribed off-label.  Some patients require continuous antibiotic treatment to maintain remission of their symptoms, which is undesirable due to the side effects of the drugs and the increased likelihood for developing antibiotic-resistant bacteria.  Enterologics will develop E. coli M17 as a maintenance therapy alternative to long-term use of antibiotics and their associated risks. The IND will permit the Company to initiate its first clinical trial, as soon as manufacturing is re-established and adequate financing is in place.

Probiotics are live microorganisms (in most cases, bacteria) that are similar to or derived from beneficial microorganisms found in the human gut.  While most probiotics are sold through consumer channels without therapeutic claims, Enterologics' strategy is to obtain FDA approval for its probiotics as biologic drugs for treating specific diseases, subject to rigorous quality standards and testing in well-controlled clinical trials.

"This acquisition fulfills the first milestone in our strategy to commercialize high value probiotics as biologic drugs for specific gastrointestinal (GI) conditions.  The E. coli M17 technology coupled with the new shelf-stable dosage form we are developing with Universal Stabilization Technologies provides us with the ideal platform for our first biologic drug product," said Bob Hoerr, Enterologics' president.  "We believe that gaining FDA approval for the pouchitis indication targeted in IND should be possible with a focused clinical testing program at a reasonable cost."

Dr. Hoerr stated that the active IND for E. coli M17 means the Company can focus its resources on the clinical testing needed for FDA approval, rather than on the lengthy preclinical testing typically required for a new biologic. The acquisition also includes BioBalance's portfolio of patents, intellectual property and regulatory filings.  Terms of the deal are detailed in the Company's 8-K filing dated September 7, 2011.

About Enterologics

Enterologics, Inc (ELGO.OB) is a biotechnology company that is developing probiotics as biologic drugs for specific gastrointestinal disease indications.  Probiotics are live microorganisms, in most cases, bacteria, that are similar to or derived from beneficial microorganisms that are found in the human gut (e.g. for more information see Introduction to Probiotics). They are also called "friendly bacteria" or "good bacteria."  Enterologics intends to identify, in-license and develop unique probiotic strains for specific medical conditions, obtain regulatory approval and market these probiotics products as FDA-approved prescription drugs for specific label indications.  The first probiotic product in its portfolio is E. coli M17, which is being developed for specific gastrointestinal indications.

Contact Information

For further information, contact ir@enterologics.com or visit www.enterologics.com.

Forward-Looking Statement

Matters discussed in this release may constitute forward-looking statements. The U.S. Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation.

Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words "believe," "intend," "anticipate," "estimate," "project," "forecast," "plan," "potential," "may," "should," "expect" and similar expressions identify forward-looking statements.

The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, the consummation of the acquisition described above, the ability to obtain regulatory approval and market its products, availability of capital, management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include our ability to identify and in-license and the ability to adequately fund such targeted acquisitions. Risks and uncertainties are further described in reports filed by Enterologics, Inc with the U.S. Securities and Exchange Commission.


'/>"/>
SOURCE Enterologics, Inc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
4. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
5. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
6. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
7. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
8. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
9. Roche completes acquisition of ARIUS
10. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
11. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... the association for the California life ... st Century Cures legislation in Congress. The bill passed ... and in the Senate on December 7 by a 94-5 ... , president & CEO of Biocom: "Today, Congress ... patients around the world. The measure culminates three years of ...
(Date:12/7/2016)... AUSTIN, Texas , Dec. 7, 2016 /PRNewswire/ ... development of revolutionary immunogene therapy treatments, today announced ... healthcare practice within a leading strategic communications and ... strategic communications program. The program will combine investor ... the objective of raising the profile of Genprex ...
(Date:12/7/2016)... December 7, 2016 Regen BioPharma Inc. ... Journal of Molecular Sciences a team of scientists in ... have demonstrated that expression of NR2F6 in patients with ... for NR2F6 in patient,s cervical cancer tissue as well as ... "This is an interesting study and the first that ...
(Date:12/7/2016)... ... 07, 2016 , ... JULABO USA is inviting visitors to ... website has been designed to provide the best user-friendly experience coupled with intuitive ... product information, read educational industry content as well as share information across all ...
Breaking Biology Technology:
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
Breaking Biology News(10 mins):